Shift of conventional paradigm of heart failure treatment: from angiotensin receptor neprilysin inhibitor to sodium-glucose co-transporter 2 inhibitors?

Abstract

Current clinical guidelines for heart failure (HF) contain a new therapeutic strategy for a certain type of HF. There is a large body of evidence for the fact that certain types of drugs called sodiumglucose co-transporter 2 inhibitors may significantly improve outcomes in patients with this type of HF who received a different group of drugs. The review discusses the features of sodium-glucose co-transporter 2 inhibitors that make them successful in improving the outcomes in patients with HF. First draft submitted: 29 October 2020; Accepted for publication: 21 December 2020; Published online: 22 February 2021